Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2007-06-05
2007-06-05
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S183100, C424S178100, C424S182100, C424S192100, C424S193100, C514S002600, C514S885000, C530S391100, C530S391700, C530S402000
Reexamination Certificate
active
08765695
ABSTRACT:
A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a Vβ of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.
REFERENCES:
patent: 3627644 (1971-12-01), Okamoto et al.
patent: 4237224 (1980-12-01), Cohen et al.
patent: 4268434 (1981-05-01), Higerd et al.
patent: 4681870 (1987-07-01), Balint, Jr. et al.
patent: 4699783 (1987-10-01), Terman et al.
patent: 4980160 (1990-12-01), Goldberg et al.
patent: 5091091 (1992-02-01), Terman
patent: 0355047 (1990-02-01), None
patent: 88/00263 (1988-01-01), None
patent: 9104053 (1991-04-01), None
patent: 91/10680 (1991-07-01), None
patent: 9201470 (1992-02-01), None
patent: 9301302 (1993-01-01), None
patent: 9314634 (1993-08-01), None
patent: 9324136 (1993-12-01), None
Forsberg et al., Brit. J. Cancer, 85:129-136, 2001.
Newton et al., The Journal of Immunol., 157:3988-3994, 1996.
Letter of Aug. 27, 1998 to European Patent Office by Opponent David Terman vs. Proprietor Pharmacia & Upjohn AB re Opponent's Comments in Response to Invitation to File Observations on the Patentee's Submissions, re. Opposition to European Patent No. EP-B-444186 (90914564.1).
Todd et al., Toxic Shock Syndrome Associated with Phage-Group I Staphylococci Lancet 2: 116-120 (1978).
Shands et al., Toxic Shock Syndrome in Menstruating Woman: Association with Tampon Use andStaphylococcus aureusand Clinical Features in 52 Cases New Engl, J. Med. 303 1436-1441 (1980).
Fisher et al., Cardio-respiratory Failure in Toxic Shock Syndrome: Effect of Dobutamine Critical Care Medicine 13: 160-165 (1985).
Bergdoll et al., A New Staphylococcus Enterotoxin, Enterotoxin F, Associated with the Toxic Shock SyndromeStaphylococcus aureusIsolates Lancet 2 1017-1021 (1981).
Willoughby et al., The Toxic Shock Syndrome and Streptococcal Pyrogenic Exotoxins Ann. Int. Med. 98: 559 (1983).
Cone et al., Clinical and Bacteriological Observations of a Toxic Shock-Like Syndrome due toStreptococcus pyrogenesNew Engl. J. Med. 317: 146-148 (1987).
Stevens et al., Severe Group A Streptococcal Infections Associated with a Toxic Shock-like Syndrome and Scarlet Fever Toxin A New Engl J. Med 32: 321: 1-7 (1989).
Schilievert, PM Staphylococcal Enterotoxin B and Toxic Shock Syndrome Toxin-1 are Significantly Associated with Non-Menstrual TSS Lancet 1: 1149-1150 (1986).
Johnson et al., Mol. Gen. Genet. 203, 354 to 356 (1986).
Borja et al., Biochemistry vol. 6, No. 5, pp. 1467 to 1473, 1967.
Elsberry et al., Hemodynamics of Staphylococcal B Enterotoxaemia and Other Types of Shock in Monkeys J. Applied Physiology 27 164-169.
Liu et al., Cardiovascular and Vomiting Responses to a Lethal Intravenous Dose of Staphyloenterotoxin A in Rhesus Monkeys J Med Primatol. 5: 353-359 (1976).
Eur. J. Immunogenetics 19: 181-285 (1992).
Acolla RJ et al., J. Exp. Med. 157: 1053-1058 (1983).
Kavathas et al., Gamma Ray-induced Loss of Expression of HLA and Glyoxalase I Alleles in Lymphoblastoid Cells Proc. Natl. Acad. Sci. USA 77: 4251-4255 (1980).
Acolla et al., J. Exp. Med. 162: 1117-1133 (1985).
Acolla et al., J. Exp. Med. 164: 369-374 (1986).
Acolla et al., Proc. Natl. Acad. Sci. USA 82: 5145-5149 (1985).
Shoemaker et al., Development of Human Tumour Cell Line Panels for use in Disease-Oriented Drug Screening in T. Hall editor Prediction of Response to Cancer Therapy Alan Liss N.Y. pp. 265-286 (1988).
Paull K.D. et al., J. Natl. Cancer Inst. 81: 1088-1092 (1989).
Alley M.C. et al., Cancer Res. 48: 589-601 (1988).
Scudiero D.A. et al., Cancer Res. 48: 4827-4833 (1988).
Developmental Therapeutics Program Division of Cancer Treatment, National Cancer Institute Proceedings of Workshop on “Selection, Characterisation and Quality Control of Human Tumour Cell Lines from the NCI's New Drug Screening Program” Bethesda, MD May 27-28, 1-73 (1987).
Boyd M.R. Status of NCI preclinical antitumour drug discovery screen in DeVita V.T., Hellman S., Rosenberg S.A., eds Cancer: Principles and Practice of Oncology Updates, vol. 3, No. 10, Lippincott, Philadelphia 1-12 (1989).
Rooney C., et al., J. Natl. Cancer Inst. (1986).
Sausville E.A. in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval B. Teicher editor, Human Press, Totowa, N.J.
D. Terman et al., “Preliminary Observations of the Effects on Breast Adenocarcinoma of Plasma Perfused Over Immobilized Protein A,” New Eng. J. Med., 305:1195-1200 (1981).
F. Chu et al., “Purification and Characterization of Staphylococcal Enterotoxin A,” Biochem., 5:3281 (1966).
M. Bergdoll et al., “Identification of a New Enterotoxin as Enterotoxin C,” J. Bacteriol., 90:1481 (1965).
C. Borja and M. Bergdoll, “Purification and Partial Characterization of Enterotoxin C Produced byStaphylococcus aureusStrain 137,” Biochem., 6:1467 (1967).
R. Avena and M. Bergdoll, “Purification and Some Physicochemical Properties of Enterotoxin C,Staphylococcus aureusStrain 361,” Biochem., 6:1474 (1967).
E. Schantz et al., “Purification and Some Chemical and Physical Properties of Staphylococcal Enterotoxin A.” Biochem., 11:360 (1972).
E Schantz et al., “Purification of Staphylococcal Enterotoxin B,” Biochem., 4:1011 (1965).
H-C. Chang and M. Bergdoll, “Purification and Some Physicochemical Properties of Staphylococcal Enterotoxin D,” Biochem., 18:1937 (1979).
C. Borja et al., “Purification and Some Physicochemical Properties of Staphylococcal Enterotoxin E,” J. Biol. Chem., 247:2456 (1972).
M. Dayhoff (ed.), Data Section,in Atlas of Protein Sequence Structure5:D227, National Biomedical Research Foundation, Washington, D.C. (1972).
I. Huang and M. Bergdoll, “The Primary Structure of Staphylococcal Enterotoxin B,” J. Biol. Chem., 245:3493 (1970).
M. Bergdoll et al., “Enterotoxin Synthesis by the Staphylococci,”In Recent Advances in Staphylococcal Research(W.W. Yotis, ed.), Ann. N.Y. Acad. Sci., 236:307.
J. Iandolo, “Genetic Analysis of Extracellular Toxins ofStaphylococcus aureus,” Ann. Rev. Microbiol., 43:375 (1989).
M. Bergdoll et al., “Staphylococcal Enterotoxin B, III. The Physicochemical Properties and the N—and C-Terminal Amino Acid Sequences,” Arch. Biochem. Biophys., 112:104 (1965).
I. Huang et al., “Amino Acid Composition and Terminal Amino Acids of Staphylococcal Enterotoxin C,” Biochem., 6:1480 (1967).
M. Bergdoll et al., “Chemistry of the Staphylococcal Enterotoxins,” J. Agric. Food Chem., 22:9 (1974).
D. Blomster-Hautamaa et al., “Preparation of Toxic Shock Syndrome Toxin-1,” Methods in Enzymology 165:37 (1988).
M. Bergdoll et al., “Identification of Enterotoxin E,” Infect. Immun., 4:593 (1971).
M. Bergdoll, “Enterotoxins,”in Staphylococci and Staphylococci Infections(C.S.F. Easmon and C. Adlam, eds.), pp. 559-598 (1983).
J. Freer and J. Arbuthnott, “Toxins ofStaphylococcus aureus, ” Pharmac. Ther., 19:55 (1983).
L. Johnson et al., “Streptococcal Pyrogenic Exotoxin Type A (scarlet fever toxin) is related toStaphylococcus aureusEnterotoxin B,” Mol. Gen. Genet., 203:354 (1986).
W. Pearson and D. Lipman, “Improved Tools for Biological Sequence Comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444 (1988).
J. Lipman and W. Pearson, “Rapid and Sensitive Protein Similarity Searches,” Sci., 227:1435 (1985).
C. Janeway, Jr. et al., “T-Cell Responses to Mls and to Bacterial Proteins that Mimic its Behavior,” Immunol. Rev., 107:61-88.
J. Yagi et al., “Bacterial Proteins That Mediate the Association of a Defined Subset of T Cell Receptor:CD4 Complexes With Class II MHC,” J. Immunol., 144:892-901.
H. Stewart et al.,in Atlas of Tumor Pathol
Abrahmsen Lars
Bjork Per
Dohlsten Mikael
Kalland Terje
Active Biotech AB
Fulbright & Jaworski LLP
Schwadron Ronald B.
LandOfFree
Conjugate between a modified superantigen and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugate between a modified superantigen and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugate between a modified superantigen and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3843033